SanegeneBio raises $110M in follow-up to metabolic deal with Lilly
SanegeneBio在与礼来达成代谢领域合作后再筹集1.1亿美元

Just a month after announcing a deal with Eli Lilly to work on RNAi drugs for metabolic diseases, SanegeneBio has disclosed a $110 million Series B round to fund its work.
在宣布与礼来合作开发代谢性疾病RNAi药物仅一个月后，SanegeneBio披露完成1.1亿美元的B轮融资以支持其研发工作。